Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases.
about
Whole brain radiotherapy for the treatment of newly diagnosed multiple brain metastasesChemotherapy for brain metastases from small cell lung cancerWhole brain radiotherapy for the treatment of multiple brain metastasesClinical practice guideline on the optimal radiotherapeutic management of brain metastasesRedox Homeostasis and Cellular Antioxidant Systems: Crucial Players in Cancer Growth and TherapyCombining radiotherapy with sunitinib: lessons (to be) learnedMolecular and Genetic Predictors of Breast-to-Brain Metastasis: Review and Case PresentationPhase 1/2 trials of Temozolomide, Motexafin Gadolinium, and 60-Gy fractionated radiation for newly diagnosed supratentorial glioblastoma multiforme: final results of RTOG 0513.Motexafin gadolinium in the treatment of brain metastasesSystemic therapy of brain metastases: non-small cell lung cancer, breast cancer, and melanoma.Society for Neuro-Oncology 2014 annual meeting updates on central nervous system metastasesTexaphyrins and water-soluble zinc(II) ionophores: development, mechanism of anticancer activity, and synergistic effectsResection versus radiosurgery for patients with brain metastases.EFNS Guidelines on diagnosis and treatment of brain metastases: report of an EFNS Task Force.Gemcitabine twice weekly as a radiosensitiser for the treatment of brain metastases in patients with carcinoma: a phase I studyWhole brain radiotherapy with radiosensitizer for brain metastasesCurrent management of metastatic brain diseaseRadiation therapy for brain metastases in breast cancer patients.Efficacy and safety of antitumor agents plus radiotherapy compared with radiotherapy alone for brain metastases from lung cancer.The role of emerging and investigational therapies for metastatic brain tumors: a systematic review and evidence-based clinical practice guideline of selected topics.Rationale for the use of upfront whole brain irradiation in patients with brain metastases from breast cancer.Motexafin gadolinium enhances the efficacy of aminolevulinic acid mediated-photodynamic therapy in human glioma spheroids.Predicting compliance and survival in palliative whole-brain radiotherapy for brain metastases.Estimated risk of perihippocampal disease progression after hippocampal avoidance during whole-brain radiotherapy: safety profile for RTOG 0933.Preservation of memory with conformal avoidance of the hippocampal neural stem-cell compartment during whole-brain radiotherapy for brain metastases (RTOG 0933): a phase II multi-institutional trial.Synthesis and anticancer properties of water-soluble zinc ionophores.Palliative radiation therapy in the management of brain metastases, spinal cord compression, and bone metastasesPhase I trial of motexafin gadolinium and doxorubicin in the treatment of advanced malignanciesIntegration of chemotherapy into current treatment strategies for brain metastases from solid tumors.Significance of targeted therapy and genetic alterations in EGFR, ALK, or KRAS on survival in patients with non-small cell lung cancer treated with radiotherapy for brain metastasesCognition in patients with newly diagnosed brain metastasis: profiles and implications.EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer.Six degrees of separation: the oxygen effect in the development of radiosensitizers.A phase 1b trial of the combination of the antiangiogenic agent sunitinib and radiation therapy for patients with primary and metastatic central nervous system malignancies.Real-time pretreatment review limits unacceptable deviations on a cooperative group radiation therapy technique trial: quality assurance results of RTOG 0933."Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer.The biology of brain metastases-translation to new therapiesUpfront association of carboplatin plus pemetrexed in patients with brain metastases of lung adenocarcinoma.The molecular biology of brain metastasisSerum Biomarkers Associated with Clinical Outcomes Fail to Predict Brain Metastases in Patients with Stage IV Non-Small Cell Lung Cancers.
P2860
Q24200466-A3A28415-ECC1-4B6F-B6F5-444D9CDA9641Q24202771-B5386FBF-8063-4F2E-BD41-666662004CE6Q24245002-A26991B0-B423-4B09-8978-0105F2261415Q24798845-22E3C30B-5313-4004-8083-C84FC8263BA1Q26740191-F4271133-33D4-4875-A5D5-1EF29B8C51F0Q26800587-15928425-AF5D-4D9B-9B6D-1A3F74A69C06Q26800626-7B034886-385A-41FE-9086-B7AEFEE03B19Q27310843-48CE8BD2-76E8-4507-AE15-90A7B0876DA0Q28285963-696CC6F4-3600-4C0B-8913-4B842A3C1293Q30239901-687B838B-0F60-4A7F-80C4-11BED90BB1D8Q30356590-FAD9E2D0-9426-46E1-8817-55CE9EFC241EQ30858160-E4312F53-AA11-4DBC-B2C6-73D7BF39ABF0Q31097790-CC98F066-8906-400E-8829-E75B7339AE9DQ33249813-2CD0AF65-CDD0-42FF-A969-BAB075370DB7Q33365043-C87D85AA-E619-49B2-9F13-05AAA2F11A4FQ33397865-B703074B-A0A3-49B1-82D0-BAF6CBAA1489Q33475484-DEAB5FE0-35A0-42C6-9DA9-272F077D378FQ33574565-8F9DC30D-1E7B-4946-BD62-C2A06236DF32Q33599135-CD067415-AB46-4809-969F-9A9F840656DFQ33599167-94EC0E48-4054-4EA7-BED4-CD956B69A84DQ33755725-5D3803D8-B19F-43FE-A9E2-C7C13EEDB437Q33975357-68FBE1E6-14B4-416C-A716-07FB163C131CQ34134011-666387EE-E31D-4C02-999C-DF8707A28916Q34308963-171A83E4-EAEB-4042-8652-E5AC6E9908C4Q34551025-69D3A201-599F-485E-A820-157C612474A9Q34551766-256FE9E6-1BB1-4D8E-9EC2-847B07115CBFQ34566891-A86731C3-7019-4097-B550-E0A171AF19F2Q34570658-152CD70F-1886-4B76-BA8D-C72A860543EAQ34872345-B2C6B011-0009-46E3-9879-EF7838524898Q34886787-608FC318-8BD3-461D-9CC7-D9ACC4E2A88AQ34972626-BB41D420-66ED-4315-96AD-4AC5E95BC575Q34992513-B3EB4FF3-EC47-468B-B5C8-9B06A0F0FACEQ35116798-E4FBE745-D004-408C-8213-7EAE380A217AQ35207344-964445EF-3E57-455B-A85A-10F4E50B504BQ35542459-0F8D25C6-45F5-4E63-9D69-34F11E76A639Q35570245-9B3235D6-00E9-4874-8D01-A587039F6443Q35676602-A05AA690-F43C-4DC3-9247-7E552D4AF6E3Q35845236-F2495B20-54CE-41C6-912D-A8616C9231D1Q35864968-886FFD25-5A09-4541-99F8-D0ED8724D0E1Q35885064-1CE9AC7C-76D6-4196-8549-A6FCAAD0EDDD
P2860
Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
name
Survival and neurologic outcom ...... n therapy in brain metastases.
@ast
Survival and neurologic outcom ...... n therapy in brain metastases.
@en
type
label
Survival and neurologic outcom ...... n therapy in brain metastases.
@ast
Survival and neurologic outcom ...... n therapy in brain metastases.
@en
prefLabel
Survival and neurologic outcom ...... n therapy in brain metastases.
@ast
Survival and neurologic outcom ...... n therapy in brain metastases.
@en
P2093
P356
P1476
Survival and neurologic outcom ...... n therapy in brain metastases.
@en
P2093
Andrea Bezjak
C H J Terhaard
Christopher Schultz
Jennifer Smith
Luis Souhami
Mark Leibenhaut
Markus F Renschler
Patrick Rodrigus
P304
P356
10.1200/JCO.2003.12.122
P407
P577
2003-07-01T00:00:00Z